Cue Biopharma Signs Clinical Trial Collaboration with Merck to Evaluate CUE-101 + Keytruda (pembrolizumab) as 1L Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
Shots:
- Cue Biopharma will conduct a P-I KEYNOTE-A78 study assessing the combination therapy as 1L treatment for HPV+ advanced head and neck cancer. KEYNOTE-A78 will be conducted in parallel with the ongoing P-I study assessing CUE-101 as monothx. post 1L treatment
- The ongoing P-I dose-escalation and expansion study assessing CUE-101 as a monothx. in post 1L recurrent/m-HNSCC patients to be amended to include combination therapy as 1L treatment
- The data from early patient cohorts in P-I monothx. study demonstrated tolerability and drug exposure and provides drug activity consistent with projections based on preclinical data. The company is expecting the initial PD data from P-I monothx. part of the study in H1’20
Click here to read full press release/ article
Ref: PRNewswire | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com